Vaccines remain one of the most powerful tools in global health, but scientific innovation is still needed to address emerging challenges, increase access, and improve public confidence.
Scrip-PartneredContent(Free): Strengthening the Future of Vaccines
Strengthening vaccine development, distribution, and trust is vital to safeguard public health and ensure preparedness against future pandemics, while also fostering innovation and global collaboration across nations.
Listen to this article
Vaccines remain one of the most powerful tools for protecting populations worldwide, yet the global health community faces pressing challenges in ensuring equitable access, sustainable production, and public confidence. This article explores how the vaccine ecosystem is evolving.
Keep up with the top pharma business news of the week. On the go.
More from Scrip
in the expanding and competitive field of obesity therapy clinical trials, one trend is increasingly causing a headache: placebo-arm participants dropping out or using “off-protocol” weight-loss treatments while on trial.
Sponsored by :
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
More from Business
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.